Responding to the announcement that COVAX has received more funding and is planning to accelerate its vaccine rollout,
projecting it will reach 23 percent of people with COVID vaccines in mostly developing countries by the end of the year,
Oxfam International’s Head of Inequality Policy, Max Lawson, said:
“More funding for COVAX and a quicker rollout of vaccines is a small piece of good news for developing countries
struggling to get the doses they need, but at best fewer than a quarter of people in these countries will have been
vaccinated by the end of the year.
“A lot of COVAX's doses are donations from rich countries, which doesn’t change the fact that there aren’t enough
vaccines bring produced to protect the world at the speed we need.
“If pharmaceutical companies with successful vaccines were made to share their science and know how, many countries
could be making their own vaccines, rather than being solely dependent on doses from COVAX. While the UK, Germany and
the EU are busy vaccinating their citizens, it is totally unfair that they continue to block proposals to remove the
intellectual property barriers that would allow this to happen.
“COVAX is also paying monopoly prices for the vaccines it is buying; if vaccine patents were waived prices would be far
lower, meaning far more people could be vaccinated. Yet unlike the WHO, COVAX leadership have consistently failed to
challenge Big Pharma monopolies or to support waiving patents.”